Revolution Medicines' Daraxonrasib Hits Phase 3 Survival Goals in Pancreatic Cancer
Revolution Medicines announced that daraxonrasib, its experimental oral RAS inhibitor, met key overall survival endpoints in a late-stage clinical trial for pancreatic cancer, a disease where median survival after diagnosis is typically measured in months and where few meaningful therapeutic advances have been made in decades.
Bloomberg reported that the drug nearly doubled overall survival in the pivotal study. The company characterised the results as 'unprecedented', a description echoed across specialist oncology and financial media. Revolution Medicines stock rose approximately 36% on the news, according to Barron's.
Pancreatic cancer is driven by RAS mutations in the substantial majority of cases, making it a logical target for RAS inhibition. Earlier-generation drugs struggled to block RAS effectively; Revolution Medicines has been among a small cohort of biotechs attempting to address that gap with a newer class of inhibitors.
The phase 3 data move daraxonrasib closer to a potential regulatory submission. Investors will now focus on the full dataset presentation, the precise survival curves, and whether the company pursues a partnership or advances toward commercialisation independently.
